Delic Holdings Corp subsidiary, Delic Labs, has received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on psychedelic and other compounds.
The compounds include MDMA, LSD, DMT, mescaline and 2C-B. Delic Labs has also received a Health Canada 56 exemption to acquire 60 grammes of psilocybin mushrooms from Nectar Health Sciences Laboratory Division., a wholly-owned subsidiary of Psilobrain Therapeutics Inc.
The latest exemptions enable the company to develop innovative analytical methods for psychedelic research.
Dr Markus Roggen, co-founder of Delic Labs, commented: ”Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds.
”Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercialising the research once our Dealer’s License is secured.”
Last year, the lab applied for a Dealer’s License with the intent of commercialising psilocybin research and associated intellectual property (IP) for medical and research purposes.
The Company aims to establish consistent quality control standards as more patients and clinicians incorporate psychedelic compounds into treatment plans.
Delic Labs, founded by award-winning chemist, Dr Roggen, and UBC Professor, Dr Glenn Sammis, is the engine of innovation for Delic Corp, conducting research and developing new product lines and IP. The Company’s latest foray into psilocybin research reaffirms its commitment to advancing extraction methods, analytical testing and chemical process development.
[activecampaign form=52]
